undamentalytics Newsletter
Sign in

Gyre Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Gyre Therapeutics, Inc. had total assets of $220m, total liabilities of $31.4m and shareholders' equity of $62.5m. It held $49.2m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents84166107332143130442534124943
Receivables———100——32515203128
Inventory——————————6461011
Total current assets—218198128942391249051505765149122
Total assets—263258190146340125955685117125220199
Accounts payable—53210116600011
Deferred revenue (current)—82582—20—2000010
Total current liabilities—9979111129518141220202429
Short-term debt—2111——————————
Long-term debt—12100—————————
Total debt033210500000000
Total liabilities—17184141139519151338273134
Shareholders' equity6992174−93−103−10931120764143−166362108
Non-controlling interests and other (assets − liabilities − equity)———269238109————30943512657
Shares outstanding—58m67m67m——6m24m44m63m—77m86m91m106m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: GYRE vs NAGEETON vs GYREGYRE vs ZVRA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gyre Therapeutics, Inc.